An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
Inclusion Criteria:
Participants under enrollment and treatment in an avelumab clinical study under the sponsorship of EMD Serono Research & Development Institute, Inc. / Merck KGaA, Darmstadt, Germany
Participants currently enrolled in an avelumab parent study and are on active treatment with avelumab or in long-term survival follow-up after treatment
Participants on active treatment must agree to continue to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) for both male and female participants if the risk of conception exists
Other protocol defined inclusion criteria could apply.
Exclusion Criteria:
Sacramento, California 95817, United States
Port Saint Lucie, Florida 34952, United States
Greenville, South Carolina 29605, United States
Burlington, Vermont 05401, United States
Ciudad Autonoma Buenos Aires, Argentina
Pessac, France
Naples, Italy
Habikino-shi, Japan
Kurume-shi, Japan
Suita-shi, Japan
Warsaw, Poland
Cluj-Napoca, Romania
Comuna Floresti, Romania
Kursk, Russia
Saint Petersburg, Russia
Istanbul, Turkey (Türkiye)
Kherson, Ukraine